In accordance to our previous short term (one week) study in an acute glomerulonephritis model [15], we now demonstrate that the apparent competition of long-term TSP-2 therapy with endogenously increased TSP-1 was able to specifically inhibit TGF-β activation in CAN as assessed at the end point 7 months after application. The gene discussed is THBS1; the disease is glomerulonephritis.